Alzheimer's Disease Research Center

西奈山发展研究中心(SANO)：总体-研究总结 阿尔茨海默病(AD)是威胁国家和世界健康的重大疾病，给人类带来巨大的痛苦和痛苦。 经济损失。虽然在检测和提高认识方面取得了一些进展，但寻找治疗方法 尽管进行了几十年的研究，但仍然没有成功。到目前为止，努力的重点是定义这种疾病 通过对终末期病理的狭隘描述，使用限制性样本和技术 系统地排除疾病的多样性。这种方法已经导致了多个失败，导致很少 治疗方面的进展。在此背景下，西奈山阿尔茨海默病研究中心 (MSADRC)，凭借其在治疗开发方面的成功历史，再次致力于识别和开发 治疗阿尔茨海默病的有效方法。位于曼哈顿的西奈山校区和布朗克斯区的 詹姆斯·J·彼得斯退伍军人管理局医疗中心，我们将两家首屈一指的机构的实力带到了 寻找治疗阿尔茨海默病的任务。这一应用程序建立在这些机构优势的基础上，包括系统- 基于科学研究的方法，使用计算工具挖掘大数据和我们已建立的 在招募不同人群方面的专业知识。我们提出的主题是：了解疾病的异质性 优化治疗方法来治疗和治愈阿尔茨海默病“，因为它使我们的力量与 《国家阿尔茨海默氏症项目法》的实施领域和里程碑。我们建议使用7核 (行政、临床、生物标记、遗传学、神经病理学、数据和外展)和研究教育 所有这些部门都有出色的领导层，反映出新招聘的教员以及调查人员 在MSADRC有既定的历史。利用临床和外展核心的协作努力，增强 通过在两个地点通过电子医疗记录让患者参与进来的新方法，我们建议 扩大和维持450名不同的个人，其中40%将来自代表性不足的少数族裔， 所有患者都接受年度临床评估、基因分析和血液生物标记物收集。遗传学的核心将 收集ALL的遗传学数据，生成GWA，并将为已建立的生物标记物和 在这个不同的队列中的蛋白质组学。我们新的Biomarker Core，由新的慈善事业和现有研究支持 将努力获得所有患者的结构和功能成像，并使用脑脊液生物标记物进行分子表型鉴定 或对至少50%的队列进行分子成像，捕捉其全部多样性。神经病理核心， 将收集范围从大脑扩大到其他相关组织和尸检时获得的体液，将使 为无偏系统采样(体视学)和尸检衍生的相关脑区做准备 用于iPS、多组学、微生物组和外切体研究的标本。数据核心，通过添加 作为核心联席主管的科学计算和数据科学高级副院长将扩大能力，以 整合和共享核心的资源，以促进跨学科合作并创造环境 这促进了寻找治疗和治愈方法的创新方法。

Mount Sinai ADRC (Sano): OVERALL – Research Summary Alzheimer's disease (AD) is a major health threat to the nation and the world causing great human pain and economic loss. While some advances have been made in detection and raising awareness, finding treatments has remained unsuccessful in spite of decades of research. To date, efforts have focused on defining the disease by a narrow characterization of end-stage pathology, using restrictive samples and technologies that systematically exclude the diversity of the disease. This approach has led to multiple failures, resulting in scant progress on the therapeutic front. With this backdrop, the Mount Sinai Alzheimer's Disease Research Center (MSADRC), with its history of success in therapeutic development dedicates itself anew to identify and develop effective approaches to treating AD. Co-located in Manhattan on the Mount Sinai campus and in the Bronx at the James J Peters Veterans Administration Medical Center, we bring the strength of two premiere institutions to the mission of finding a treatment for AD. This application builds on these institutional strengths including systems- based approaches to scientific inquiry, using the computational tools to mine big data and our established expertise in recruiting diverse populations. We propose as our theme “Understanding disease heterogeneity to optimize therapeutic approaches to treat and cure Alzheimer's disease” as it aligns our strengths with the implementation areas and milestones of the National Alzheimer's Project Act (NAPA). We propose 7 cores (Administrative, Clinical, Biomarker, Genetics, Neuropathology, Data, and Outreach) and a Research Education Component, all of which have outstanding leadership reflecting newly recruited faculty as well investigators with established histories at the MSADRC. Using the collaborative efforts of the Clinical and Outreach Core, enhanced by novel methods of patient engagement through the electronic medical records at both locations, we propose to expand and maintain a cohort of 450 diverse individuals, 40% of whom will be from under-represented minorities, all receiving annual clinical evaluations, genetic analysis, and blood biomarker collection. The Genetics Core will collect genetics data on all, generate GWAS, and will obtain plasma samples for established biomarkers and proteomics on this diverse cohort. Our new Biomarker Core, supported by new philanthropy and existing research efforts will obtain structural and functional imaging on all patients, and molecular phenotyping with CSF biomarkers or molecular imaging on at least 50% of the cohort, capturing its full diversity. The Neuropathology Core, expanding collection beyond brain to other relevant tissues and body fluids obtained at autopsy, will allow the preparation of relevant brain regions for unbiased systematic sampling (stereology) and autopsy-derived specimens for iPS, multiomics, microbiome, and exosome studies. The Data Core, enhanced by the addition of the Senior Associate Dean for Scientific Computing and Data Science as Core Co-Leader, will expand the capacity to integrate and share the Core's resources to facilitate interdisciplinary collaborations and create an environment that fosters innovative approaches to finding treatments and cures.